Last reviewed · How we verify

Xdemvy — Competitive Intelligence Brief

Xdemvy (LOTILANER) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ectoparasiticide [EPC]. Area: Other.

marketed Ectoparasiticide [EPC] Other Small molecule Live · refreshed every 30 min

Target snapshot

Xdemvy (LOTILANER) — Tarsus. Xdemvy works by targeting and killing Demodex mites that cause blepharitis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xdemvy TARGET LOTILANER Tarsus marketed Ectoparasiticide [EPC] 2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ectoparasiticide [EPC] class)

  1. Tarsus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xdemvy — Competitive Intelligence Brief. https://druglandscape.com/ci/lotilaner. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: